×
About 263 results

ALLMedicine™ Neurotrophic Keratopathy Center

Research & Reviews  103 results

Minimally invasive corneal neurotization provides sensory function, protects against re...
https://doi.org/10.1016/j.ajo.2022.04.013
American Journal of Ophthalmology; Haur WJ, Christian DS et. al.

May 6th, 2022 - To measure sensory recovery after minimally invasive corneal neurotization and to identify and quantify the extent to which patient and technical factors influence sensory recovery, ulceration rate, and visual outcomes. Retrospective case series M...

Clinical and instrumental assessment of the corneal healing in moderate and severe neur...
https://doi.org/10.1177/11206721221097584
European Journal of Ophthalmology; Roszkowska AM, Inferrera L et. al.

Apr 28th, 2022 - To evaluate corneal healing in patients with moderate and severe neurotrophic keratitis (NK) treated with topical rh-NFG (Cenegermin). Twenty-one patients (12F and 9M) aged from 21 to 93 years (62.5 ± 19.4) with moderate and severe NK were enrolle...

Topical cenegermin 0.002% for pediatric neurotrophic keratopathy.
https://doi.org/10.1177/11206721221094783
European Journal of Ophthalmology; Elhusseiny AM, Traish AS et. al.

Apr 27th, 2022 - To evaluate the efficacy and safety of cenegermin 0.002% ophthalmic drops in the management of pediatric neurotrophic keratopathy (NK). Retrospective chart review of children under the age of 18 years diagnosed with NK at Boston Children's Hospita...

Cutting Edge: Topical Recombinant Nerve Growth Factor for the Treatment of Neurotrophic...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9106815
Cornea Hamrah P, Yavuz Saricay L et. al.

Mar 11th, 2022 - Ophthalmologists find management of neurotrophic keratopathy (NK) challenging because conventional therapy lacks efficacy and may result in permanent loss of vision. Recombinant nerve growth factor (cenegermin) targets the underlying pathogenesis ...

Eight months follow-up of corneal nerves and sensitivity after treatment with cenegermi...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8862484
Orphanet Journal of Rare Diseases; Pedrotti E, Bonacci E et. al.

Feb 23rd, 2022 - Cenegermin (Oxervate, Dompè Farmaceutici, Milan, IT), a recombinant human NGF, is a potentially healing new drug for neurotrophic keratopathy (NK), a rare but challenging disease affecting the cornea. To date, studies that evaluate its mid-term ef...

see more →

Clinicaltrials.gov  2 results

Topical Insulin - Utility and Results in Neurotrophic Keratopathy in Stages 2 and 3
https://clinicaltrials.gov/ct2/show/NCT04820010

Apr 27th, 2021 - Study type Retrospective, observational, single-center study at the Department of Ophthalmology of Centro Hospitalar Vila Nova de Gaia e Espinho, EPE. Data was obtained from patients' medical records and anterior segment photographs from October 1...

Assessment of the Safety and Efficacy Study of RGN-259 Ophthalmic Solutions for Neurotrophic Keratopathy : SEER-1
https://clinicaltrials.gov/ct2/show/NCT02600429

Jul 2nd, 2020 - Neurotrophic keratopathy (NK) is a degenerative corneal disease that occurs as a result of partial or total impairment of trigeminal innervation. The resulting loss of corneal sensitivity (anesthesia) leads to a reduction in lacrimation and a decl...

see more →